{"question": "What percentage of tumors showed HER-2/neu amplification?", "answer": "HER-2/neu was amplified in approximately 30% of the tumors.", "ground_truth_context": ["HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated.", "This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors.", "Amplification of the HER-2/neu gene was measured as in the initial survey, and examples of tumors from this study are shown. Amplification was found in 34/86 (40%) of these patients."]}
{"question": "What is the molecular weight of the HER-2/neu protein?", "answer": "The HER-2/neu protein is 185,000 daltons.", "ground_truth_context": ["Finally, the protein encoded by the HER-2/neu gene is 185,000 daltons, as compared to the 170,000-dalton protein encoded by the EGFR gene.", "Also, the HER-2/neu gene generates a messenger RNA (mRNA) of 4.8 kb, which differs from the 5.8- and 10-kb transcripts for the EGFR gene. Finally, the protein encoded by the HER-2/neu gene is 185,000 daltons, as compared to the 170,000-dalton protein encoded by the EGFR gene."]}
{"question": "How does HER-2/neu copy number relate to survival times?", "answer": "Patients with greater than five copies of HER-2/neu had shorter disease-free and overall survival times.", "ground_truth_context": ["Patients with greater than five copies of HER-2/neu had even shorter disease-free survival times (P = 0.015) and overall survival times (P = 0.06) when compared to patients with no amplification.", "While there was a somewhat shortened time to relapse and shorter overall survival in patients having any amplification of the HER-2/neu gene in their tumors, the greatest differences were found when comparing patients with >5 copies of the gene to those without amplification (single copy).", "Finally, the degree of HER-2/neu amplification appears to have an effect on survival, with greater copy number being associated with a worse prognosis."]}
{"question": "What is the incidence rate of EGFR amplification compared to HER-2/neu?", "answer": "EGFR amplification was found in 2% of tumors, whereas HER-2/neu was amplified in about 28\u201330%, making HER-2/neu amplification 14 times more common.", "ground_truth_context": ["Amplification of the EGFR gene was found in 4/189 (2%) of the cases, and rearrangement of the EGFR gene was found in one of those four cases. The incidence of EGFR amplification and rearrangement was too small to attempt statistical correlation.", "To determine whether the phenomenon of amplification of HER-2/neu in breast cancer extended to related growth factor receptors, all filters were analyzed with the EGFR probe. Amplification of the EGFR gene was found in 4/189 (2%) of the cases, and rearrangement of the EGFR gene was found in one of those four cases."]}
{"question": "How does HER-2/neu compare to estrogen receptor status in prognosis?", "answer": "HER-2/neu amplification had greater prognostic value than estrogen receptor status in lymph node-positive breast cancer.", "ground_truth_context": ["Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease.", "Moreover, amplification of HER-2/neu has greater prognostic value than most currently used prognostic factors, including progesterone and estrogen receptors, and is equivalent to and independent of the best known prognosticator: number of positive lymph nodes."]}
{"question": "What makes HER-2/neu different from EGFR at the molecular level?", "answer": "HER-2/neu is located on chromosome 17q21 and encodes a 185 kDa protein, while EGFR is on chromosome 7p11-13 and encodes a 170 kDa protein. Their mRNA sizes also differ.", "ground_truth_context": ["Finally, the protein encoded by the HER-2/neu gene is 185,000 daltons, as compared to the 170,000-dalton protein encoded by the EGFR gene.", "HER-2/neu differs from EGFR in that it is found on band q21 of chromosome 17, as compared to band p11-p13 of chromosome 7, where the EGFR gene is located.", "Also, the HER-2/neu gene generates a messenger RNA (mRNA) of 4.8 kb, which differs from the 5.8- and 10-kb transcripts for the EGFR gene."]}
{"question": "What method was used to assess gene amplification?", "answer": "Southern blot analysis was used to assess gene amplification using radiolabeled HER-2/neu probes.", "ground_truth_context": ["In the initial survey, tissue from 103 primary breast cancers was evaluated for alterations in the HER-2/neu gene. DNA from individual tumors was prepared as described, digested with Eco RI, and subjected to Southern blot analysis with a 32P-labeled HER-2/neu-1 probe, which is known to detect a 13-kb hybridizing band in human DNA.", "A total of 12 micrograms of Eco RI-digested DNA was loaded onto 0.8% agarose gels, separated by electrophoresis, and transferred onto nylon filter papers (Biodyne).", "All filters were baked in a vacuum oven for 3 hours at 80 degrees C, prehybridized in 5 x SSC (standard saline citrate) containing 50% formamide, 10% dextran sulfate, 0.1% SDS, denatured salmon sperm DNA (1 mg/ ml), and 4x Denhardts solution for 12 hours, then hybridized in the same solution containing 32P-labeled nick-translated HER-2 probe (21) specific activity of 1 x 10^8 cpm per microgram of DNA; 2 x 10^6 cpm/ml. Hybridization occurred at 42 degrees C for 48 hours, followed by washing of filters under the following conditions in succession: 2x SSC for 20 minutes at room temperature; two washes of 30 minutes each in 2 x SSC, 0.1% SDS at 65 degrees C; one wash of 30 minutes in 0.5x SSC, 0.1% SDS at 65 degrees C. Filters were then exposed to XAR-5 x-ray film (Kodak) for autoradiography."]}
{"question": "How was DNA prepared and visualized in this study?", "answer": "DNA was digested with Eco RI, run on agarose gels, transferred to nylon filters, and hybridized with radiolabeled probes for autoradiography.", "ground_truth_context": ["All filters were baked in a vacuum oven for 3 hours at 80 degrees C, prehybridized in 5 x SSC (standard saline citrate) containing 50% formamide, 10% dextran sulfate, 0.1% SDS, denatured salmon sperm DNA (1 mg/ ml), and 4x Denhardts solution for 12 hours, then hybridized in the same solution containing 32P-labeled nick-translated HER-2 probe (21) specific activity of 1 x 10^8 cpm per microgram of DNA; 2 x 10^6 cpm/ml. Hybridization occurred at 42 degrees C for 48 hours, followed by washing of filters under the following conditions in succession: 2x SSC for 20 minutes at room temperature; two washes of 30 minutes each in 2 x SSC, 0.1% SDS at 65 degrees C; one wash of 30 minutes in 0.5x SSC, 0.1% SDS at 65 degrees C. Filters were then exposed to XAR-5 x-ray film (Kodak) for autoradiography.", "A total of 12 micrograms of Eco RI-digested DNA was loaded onto 0.8% agarose gels, separated by electrophoresis, and transferred onto nylon filter papers (Biodyne)."]}
{"question": "What was the p-value for the correlation between HER-2/neu amplification and relapse?", "answer": "The correlation between HER-2/neu amplification and time to relapse was highly significant, with a p-value of <0.0001.", "ground_truth_context": ["A strong and highly statistically significant correlation was found between the degree of gene amplification and both time to disease relapse (P = <0.0001) and survival (P = 0.0011).", "While these correlations were of interest, the strong relationship between HER-2/neu amplification and nodal status (P = 0.002) indicated that information on amplification of this gene may correlate with disease behavior; that is, recurrences and survival. To test this, univariate survival analyses were performed in which amplification was compared to relapse and survival in this patient group."]}
{"question": "Does this paper discuss treatment using Herceptin?", "answer": "No, the paper does not mention Herceptin.", "ground_truth_context": []}
